Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. (April 2015)

• Record Type: Journal Article
• Authors: Sun, Xuejiao; He, Zhiyi; Zhang, Jianquan; Deng, Jingmin; Bai, Jing; Li, Meihua; Zhong, Xiaoning
• Is Part Of: Pulmonary pharmacology & therapeutics. Volume 31(2015:Apr.)
• Page Start: 111
• Page End: 116
• Publication Date: 2015-04
• Subjects: Chronic obstructive pulmonary disease -- Exacerbation -- Inhaled corticosteroid -- Safety; Respiratory organs -- Diseases -- Chemotherapy -- Periodicals; 615.7205
• DOI: 10.1016/j.pupt.2014.09.004
• Languages: English
• ISSNs: 1094-5539

Abstract

Abstract: Background: Corticosteroids have been shown to improve the outcome of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, whether inhaled corticosteroids (IC) alone have similar effects with systemic corticosteroid (SCS) is still unclear. Objectives: To compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Methods: 30 AECOPD patients were randomly divided into two group. Budesonide group (15 cases) were treated with inhaled budesonide (3 mg Bid); methylprednisolone group (15 cases) were treated with systemic methylprednisolone (methylprednisolone acetate injectable suspension 40 mg Qd for three days and then methylprednisolone tablets 8 mg Bid). Observe symptoms, lung function, blood gas analysis and adverse effects of the patients in two groups. Peripheral blood samples were collected before and after treatment for 1 day, 4 days and 7 days. Interleukin-8 (IL-8) and TNF-α levels were determined by an enzyme linked immunosorbent assay (ELISA). Hs-CRP levels were detected by automatic biochemical analyzer. Western blotting was used to determine histone deacetylase 2 (HDAC2) protein expression. Measurements and main results: Symptoms, pulmonary function and blood gas analysis were significantly improved after treatment in the two groups ( P < 0.05) and no significant differences between the two groups ( P > 0.05). There were no significant differences of IL-8, TNF-α and hs-CRP levels in the two groups ( P > 0.05). Besides, the levels of HDAC2 protein expression before treatment were significantly lower comparing to that after treatment for 4 and 7 days. Incidence of adverse events (heart rate, blood pressure, glycemic, sleep condition, gastrointestinal symptoms) in budesonide group was lower than methylprednisolone group ( P < 0.05). Conclusions: Inhaled budesonide and systemic methylprednisolone have the same effects on systemic inflammation of AECOPD. Inhaled corticosteroid alone could instead systemic corticosteroid in AECOPD treatment.